AstraZeneca's Nexium Faces Generic Competition

BMI View: Traditionally, multinational drugmakers have maintained high revenue streams in developed markets, such as those in Western Europe, via the sale of high-value patented medicines. While it is our view that developed markets will continue to act as the core revenue stream for drugmakers, as affordability levels remain high in these markets compared to those in emerging markets, we believe that the string of patent expiries and the availability of lower-value generic medicines will make it increasingly difficult for drugmakers to maintain the same levels of sales and profits in these markets.

To read the full article, please choose one of the following options: